Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 162 entries
View as:

A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06625593 Org: User:
Start: 12/09/24 End: 12/31/26 Due: 12/31/27

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06742996 Org: User:
Start: 03/05/25 End: 10/30/32 Due: 10/30/33

A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06761898 Org: User:
Start: 01/14/25 End: 11/05/25 Due: 11/05/26

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06685718 Org: User:
Start: 11/26/24 End: 04/30/28 Due: 04/30/29

A Study of BGB-11417 in Participants With Myeloid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04771130 Org: User:
Start: 05/24/21 End: 02/08/28 Due: 02/08/29

A Study of BG-C477 in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06596473 Org: User:
Start: 10/03/24 End: 10/27/28 Due: 10/27/29

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03432884 Org: User:
Start: 01/25/18 End: 04/16/18 Due: 04/16/19

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02795182 Org: User:
Start: 06/29/16 End: 12/18/20 Due: 12/18/21

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

Phase: N/A Priority: Normal
NCT ID: NCT04163783 Org: User:
Start: 03/29/17 End: 04/18/17 Due: 04/18/18

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06540066 Org: User:
Start: 08/30/24 End: 01/31/27 Due: 01/31/28

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04486391 Org: User:
Start: 09/01/20 End: 02/28/26 Due: 02/28/27

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Phase: N/A Priority: Normal
NCT ID: NCT04276493 Org: User:
Start: 03/26/20 End: 10/31/24 Due: 10/31/25

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04172246 Org: User:
Start: 01/29/20 End: 06/30/25 Due: 06/30/26

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

Phase: N/A Priority: Normal
NCT ID: NCT06342713 Org: User:
Start: 06/03/24 End: 02/27/26 Due: 02/27/27

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT06634589 Org: User:
Start: 11/27/24 End: 12/02/29 Due: 12/02/30

An Investigational Study of BGB-58067 in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06589596 Org: User:
Start: 10/11/24 End: 11/30/26 Due: 11/30/27

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06253195 Org: User:
Start: 04/01/24 End: 10/26/26 Due: 10/26/27

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05981703 Org: User:
Start: 09/07/23 End: 09/30/27 Due: 09/30/28

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria

Phase: N/A Priority: Normal
NCT ID: NCT07005713 Org: User:
Start: 06/30/25 End: 09/22/26 Due: 09/22/27

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02407990 Org: User:
Start: 06/02/15 End: 08/12/20 Due: 08/12/21

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06973187 Org: User:
Start: 09/30/25 End: 04/17/28 Due: 04/17/29

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05116085 Org: User:
Start: 01/26/22 End: 01/03/25 Due: 01/03/26

A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03189524 Org: User:
Start: 07/05/16 End: 08/26/20 Due: 08/26/21

Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT03358875 Org: User:
Start: 11/30/17 End: 01/18/24 Due: 01/18/25

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04716634 Org: User:
Start: 04/19/21 End: 02/22/24 Due: 02/22/25